A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 1, 2013, Pages 187-197

  Ranieri, G ^a   Gadaleta, C D ^a   Patruno, R ^b   Zizzo, N ^b   Daidone, M G ^c   Hansson, M G ^d   Paradiso, A ^a   Ribatti, D ^e  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Anticancer therapies; Comparative oncology; Dog tumors; Human tumors; Translational research

Indexed keywords

ABT 526; ASPARAGINASE; CASPASE AUTOACTIVATING COMPOUND DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; GS 9219; MAMMALIAN TARGET OF RAPAMYCIN; MASITINIB; MIFAMURTIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PRODRUG; PROTEIN DERIVATIVE; RAPAMYCIN; STEM CELL FACTOR RECEPTOR; SUNITINIB; THROMBOSPONDIN 1; TOCERANIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANINE MODEL; CLINICAL FEATURE; CROSS CIRCULATION; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; DRUG UPTAKE; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPERTHERMIA; IMMUNITY; LIMB MOVEMENT; LIVER TUMOR; LUNG TUMOR; LYMPHOCYTOMA; LYMPHOSARCOMA; MASTOCYTOMA; MOLECULAR MECHANICS; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TUMOR PROMOTION; TUMOR REGRESSION;

ANTICANCER THERAPIES; COMPARATIVE ONCOLOGY; DOG TUMORS; HUMAN TUMORS; TRANSLATIONAL RESEARCH;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; HUMANS; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84884127860     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.03.005     Document Type: Review

References (88)

1. Bankert R.B., Egilmez N.K., Hess S.D. SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Trends in Immunology 2001, 22:386-393.
2. Kung A.L. Practices and pitfalls of mouse cancer models in drug discovery. Advances in Cancer Research 2007, 96:191-212.
3. Vail D.M., MacEwen E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000, 18:781-792.
4. Ambrosini V., Quarta C., Nanni, et al. Small animal PET in oncology: the road from bench to bedside. Cancer Biotherapy and Radiopharmaceuticals 2009, 24:277-285.
5. Lindblad-Toh K., Wade C.M., Mikkelsen T.S., et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438:803-819.
6. Mendoza S., Konishi T., Dernell W.S., et al. Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Research 1998, 18:4449-4453.
7. Rivera P., Melin M., Biagi T., et al. Mammary tumor development in dogs is associated with BRCA1 and BRCA2. Cancer Research 2009, 69:8770-8774.
8. Gregory-Bryson E., Bartlett E., Kiupel M., et al. Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11. BMC 2010, 10:559.
9. Breen M., Modiano J.F. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans and man and his best friend share more than companionship. Chromosome Research 2008, 16:145-154.
10. Rowell J.L., McCarthy D.O., Alvarez C.E. Dog models of naturally occurring cancer. Trends in Molecular Medicine 2011, 17:380-388.
11. Rosol T.J., Tannehill-Gregg S.H., LeRoy B.E., et al. Animal models of bone metastasis. Cancer 2003, 97:748-757.
12. Glickman L.T., Domanski L.M., Maguire T.G., et al. Mesothelioma in pet dogs associated with exposure of their owners to asbestos. Environmental Research 1983, 32:305-313.
13. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 2008, 8:147-156.
14. Thomas E.D., Collins J.A., Herman E.C., et al. Marrow transplants in lethally irradiated dogs given methotrexate. Blood 1962, 19:217-228.
15. Epstein R.B., Storb R., Clift R.A., et al. Autologous bone marrow grafts in dogs treated with lethal doses of cyclophosphamide. Cancer Research 1969, 29:1072-1075.
16. Thomas E.D., Storb R., Epstein R.B., et al. Symposium on bone marrow transplantation: experimental aspects in canines. Transplantation Proceedings 1969, 1:31-33.
17. Thomas E.D., Fefer A., Buckner C.D., et al. Current status of bone marrow transplantation for aplastic anemia and acute leukemia. Blood 1977, 49:671-681.
18. Ponce F., Marchal T., Magnol J.P., et al. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary Pathology 2010, 47:414-433.
19. Ranieri G., Patruno R., Lionetti A., et al. Endothelial area and microvascular density in a canine non-Hodgkin's lymphoma: an interspecies model of tumor angiogenesis. Leukemia and Lymphoma 2005, 46:1639-1643.
20. Zizzo N., Patruno R., Zito F.A., et al. Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model. Leukemia and Lymphoma 2010, 51:291-296.
21. Ranieri G., Patruno R., Ruggieri E., et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Current Medicinal Chemistry 2006, 13:1845-1857.
22. Ranieri G., Gasparini G. Surrogate markers of angiogenesis and metastasis. Methods in Molecular Medicine 2001, 99-113. Humana Press. S.A. Brooks, U. Schumacher (Eds.).
23. Patruno R., Zizzo N., Zito A.F., et al. Microvascular density and endothelial area correlate with Ki-67 proliferative rate in the canine non-Hodgkin's lymphoma spontaneous model. Leukemia and Lymphoma 2006, 47:1138-1143.
24. Epstein R.B., Graham T.C., Storb R., et al. Studies of marrow transplantation, chemotherapy and cross-circulation in canine lymphosarcoma. Blood 1971, 37:349-359.
25. Ranieri G., Ruggieri E., Falco G., et al. Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma. Endocrine, Metabolic & Immune Disorders - Drug Targets 2006, 6:271-277.
26. Gadaleta C.D., Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combination with angiogenesis inhibitors. Critical Reviews in Oncology/Hematology 2011, 80:40-53.
27. Ranieri G., Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Current Drug Targets - Immune, Endocrine & Metabolic Disorders 2001, 1:241-253.
28. Rusk A., McKeegan E., Haviv F., et al. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clinical Cancer Research 2006, 12:7444-7455.
29. Rusk A., Cozzi E., Stebbins M., et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma. Clinical Cancer Research 2006, 12:7456-7464.
30. Nabors L.B., Fiveash J.B., Markert J.M., et al. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Archives of Neurology 2010, 67:313-319.
31. Vail D.M., Thamm D.H., Reiser H., et al. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma. Clinical Cancer Research 2009, 15:3503-3510.
32. Hsu D.C., Novotny C.J., West D.C., et al. Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound. Cancer Research 2010, 70:7232-7241.
33. Withrow S.J., Powers B.E., Straw RC Comparative aspects of osteosarcoma. Dog versus man. Clinical Orthopedics in Related Research 1991, 199(270):159-168.
34. Ferracini R., Angelini P., Cagliero E., et al. MET oncogene aberrant expression in canine osteosarcoma. Journal of Orthopaedic Research 2000, 18:253-256.
35. Levine R.A., Forest T., Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Veterinary Pathology 2002, 39:372-378.
36. Flint A.F., U'Ren L., Legare M.E., et al. Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors. Veterinary Pathology 2004, 41:291-296.
37. Paoloni M., Davis S., Lana S., et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009, 10:625.
38. Mueller F., Fuchs B., Kaser-Hotz B. Comparative biology of human and canine osteosarcoma. Anticancer Research 2007, 27:155-164.
39. Withrow S.J., Wilkins R.M. Cross talk from pets to people: translational osteosarcoma treatments. ILAR Journal 2010, 51:208-213.
40. Withrow S.J., Khanna C. Bridging the gap between experimental animals and humans in osteosarcoma. Cancer Treatment and Research 2009, 152:439-446.
41. Withrow S.J., Thrall D.E., Straw R.C., et al. Intraarterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 1993, 71:2484-2490.
42. Choong P.F., Sim F.H. Limb-sparing surgery for bone tumors: new developments. Seminars in Surgical Oncology 1997, 13:64-69.
43. Kleinerman E.S., Maeda M., Jaffe N. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. Cancer Treatment and Research 1993, 62:101-107.
44. Kurzman I.D., MacEwen E.G., Rosenthal R.C., et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clinical Cancer Research 1995, 1:1595-1601.
45. Meyers P.A., Schwartz C.L., Krailo M.D., et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. Journal of Clinical Oncology 2008, 26:633-638.
46. Klümpen H.J., Beijnen J.H., Gurney H. Inhibitors of mTOR. Oncologist 2010, 15:1262-1269.
47. Paoloni M.C., Mazcko C., Fox E., et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 2010, 5:1101.
48. Houghton P.J., Morton C.L., Kolb E.A. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood Cancer 2008, 50:799-805.
49. Ribatti D., Crivellato E. Mast cells, angiogenesis, and tumor growth. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2012, 1822:2-8.
50. Ranieri G., Passantino L., Patruno R., et al. The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumour malignancy. Oncology Reports 2003, 10:1189-1193.
51. Webster J.D., Yuzbasiyan-Gurkan V., Kaneene J.B. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006, 8:104-111.
52. Patruno R., Arpaia N., Gadaleta C.D., et al. VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model. Journal of Cellular and Molecular Medicine 2009, 13:555-561.
53. Antonescu C.R. The GIST paradigm: lessons for other kinase-driven cancers. Journal of Pathology 2011, 223:251-261.
54. Webster J.D., Kiupel M., Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 2006, 6:85.
55. Ranieri G., Labriola A., Achille G., et al. Microvessel density, mast cell density and thymidine phosphorylase expression in oral squamous carcinoma. International Journal of Oncology 2002, 21:1317-1323.
56. Ranieri G., Ammendola M., Patruno R., et al. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. International Journal of Oncology 2009, 35:115-120.
57. Chen S., Burgin S., McDaniel A., et al. Nf1-/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase. American Journal of Pathology 2010, 177:3125-3132.
58. Dubreuil P., Letard S., Ciufolini M., et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009, 4:e7258.
59. Hahn K.A., Ogilvie G., Rusk T., et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008, 22:1301-1309.
60. Mitry E., Hammel P., Deplanque, et al. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology 2010, 66:395-403.
61. Le Cesne A., Blay J.Y., Bui B.N., et al. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European Journal of Cancer 2010, 46:1344-1351.
62. Liao A.T., Chien M.B., Shenoy N., et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100:585-593.
63. Pryer N.K., Lee L.B., Zadovaskaya R., et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clinical Cancer Research 2003, 9:5729-5734.
64. London C.A., Hannah A.L., Zadovoskaya R., et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research 2003, 9:2755-2768.
65. Goodman V.L., Rock E.P., Dagher R., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clinical Cancer Research 2007, 13:1367-1373.
66. London C.A., Malpas P.B., Wood-Follis S.L., et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 2009, 15:3856-3865.
67. Thamm D.H., Kurzman I.D., Clark M.A., et al. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation. Clinical Cancer Research 2010, 16:1498-1508.
68. Gadaleta C., Catino A., Ranieri G., et al. Single-step therapy - feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. In Vivo 2009, 23:813-820.
69. Ahrar K., Price R.E., Wallace M.J., et al. Percutaneous radiofrequency ablation of lung tumors in a large animal model. Journal of Vascular and Interventional Radiology 2003, 14:1037-1043.
70. Gadaleta C., Mattioli V., Colucci G., et al. Radiofrequency ablation of 40 lung neoplasms: preliminary results. American Journal of Roentgenology 2004, 183:361-368.
71. Richardson R.C., Anderson V.L., Voorhees WD 3rd, et al. Irradiation-hyperthermia in canine hemangiopericytomas: large-animal model for therapeutic response. Journal of the National Cancer Institute 1984, 73:1187-1194.
72. Denman D.L., Legorreta R.A., Kier A.B., et al. Therapeutic responses of spontaneous canine malignancies to combinations of radiotherapy and hyperthermia. International Journal of Radiation Oncology, Biology, Physics 1991, 21:415-422.
73. Frew D.G., Dobson J.M., Stenning S.P. Response of 145 spontaneous canine head and neck tumours to radiation versus radiation plus microwave hyperthermia: results of a randomized phase III clinical study. International Journal of Hyperthermia 1995, 11:217-230.
74. van der Zee J., González González D., van Rhoon G.C., et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial, Dutch Deep Hyperthermia Group. Lancet 2000, 355:1119-1125.
75. Hansson M.G., Maschke K.J. Biobanks: questioning distinctions. Science 2009, 326:797.
76. Hansson M.G., Dillner J., Bartram C.R., et al. Should donors be allowed to give broad consent to future biobank research?. Lancet Oncology 2006, 7:266-269.
77. Paradiso A., Miller K., Marubini E., et al. The need for a quality control of the whole process of immunohistochemistry human epidermal growth factor receptor 2/neu determination: a United Kingdom National External Quality Assessment Service/Italian Network for Quality Assessment of Tumor Biomarkers pilot experience. Journal of Clinical Oncology 2007, 25:e27-e28.
78. Paradiso A., Mangia A., Azzariti A., et al. Phosphatidylinositol 3-kinase in breast cancer: where from here?. Clinical Cancer Research 2007, 13:5988-5990.
79. Paradiso A., Ellis I.O., Zito F.A., et al. Short- and long-term effects of a training session on pathologists' performance: the INQAT experience for histological grading in breast cancer. Journal of Clinical Pathology 2009, 62:279-281.
80. Daidone M.G., Porta C.D., Pilotti S., et al. Coexpression of survivin and TERT in soft-tissue sarcoma. Lancet 2002, 360:877.
81. Daidone M.G., Veneroni S., Cappelletti V., et al. Estrogen receptor-beta expression in hereditary breast cancer. Journal of Clinical Oncology 2002, 20:3752-3753.
82. Daidone M.G. Report of the EORTC Laboratory Research Division (LDR) Meeting: March 18, 2009, Brussels, Belgium. Breast Care (Basel) 2009, 4:273-274.
83. Mack G.S. Cancer researchers usher in dog days of medicine. Nature Medicine 2005, 11:1018.
84. Paoloni M.C., Khanna C. Comparative oncology today. Clinics of North America: Small Animal Practice 2007, 37:1023-1032.
85. Briggs J., Paoloni M., Chen Q.R., et al. A compendium of canine normal tissue gene expression. PLoS One 2011, 6:e17107.
86. Khanna C., London C., Vail D., et al. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clinical Cancer Research 2009, 15:5671-5677.
87. Khanna C., Gordon I. Catching cancer by the tail: new perspectives on the use of kinase inhibitors. Clinical Cancer Research 2009, 15:3645-3647.
88. Roberts T.G., Lynch T.J., Chabner B.A. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. Journal of Clinical Oncology 2003, 21:3683-3695.